<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>21(1)</volume><submitter>Zhang Z</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Gastric cancer (GC) is the fifth most common cancer and the third most common cause of cancer death worldwide. Plant homeodomain (PHD)-finger domain protein PHF5A has been demonstrated to play a promoting role in a variety of cancers. This study aimed to clarify the role of PHF5A in the progression of GC and its potential mechanism of action.&lt;h4>Methods&lt;/h4>Immunohistochemical staining experiments were performed based on tissues from clinical GC patients to reveal PHF5A expression. A series of functional experiments in vitro and in vivo were used to clarify the role of PHF5A in GC.&lt;h4>Results&lt;/h4>Clinically, PHF5A was abundantly expressed in GC and existed clinical value indicating poor prognosis. In addition, GC cells with knockdown of PHF5A expression showed slowed pro</pubmed_abstract><journal>Journal of translational medicine</journal><pagination>5</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9817416</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>PHF5A facilitates the development and progression of gastric cancer through SKP2-mediated stabilization of FOS.</pubmed_title><pmcid>PMC9817416</pmcid><pubmed_authors>Hua Y</pubmed_authors><pubmed_authors>Yang W</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Peng L</pubmed_authors><pubmed_authors>Luo S</pubmed_authors></additional><is_claimable>false</is_claimable><name>PHF5A facilitates the development and progression of gastric cancer through SKP2-mediated stabilization of FOS.</name><description>&lt;h4>Background&lt;/h4>Gastric cancer (GC) is the fifth most common cancer and the third most common cause of cancer death worldwide. Plant homeodomain (PHD)-finger domain protein PHF5A has been demonstrated to play a promoting role in a variety of cancers. This study aimed to clarify the role of PHF5A in the progression of GC and its potential mechanism of action.&lt;h4>Methods&lt;/h4>Immunohistochemical staining experiments were performed based on tissues from clinical GC patients to reveal PHF5A expression. A series of functional experiments in vitro and in vivo were used to clarify the role of PHF5A in GC.&lt;h4>Results&lt;/h4>Clinically, PHF5A was abundantly expressed in GC and existed clinical value indicating poor prognosis. In addition, GC cells with knockdown of PHF5A expression showed slowed pro</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-26T06:01:21.522Z</modification><creation>2025-04-06T11:42:44.683Z</creation></dates><accession>S-EPMC9817416</accession><cross_references><pubmed>36609277</pubmed><doi>10.1186/s12967-022-03821-w</doi></cross_references></HashMap>